Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

MLA

Nakajima, Atsushi, et al. “Randomised Clinical Trial: Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), versus Placebo in Patients with Non-Alcoholic Fatty Liver Disease.” Alimentary Pharmacology & Therapeutics, vol. 54, no. 10, Nov. 2021, pp. 1263–77. EBSCOhost, https://doi.org/10.1111/apt.16596.

APA

Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., & Loomba, R. (2021). Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 54(10), 1263–1277. https://doi.org/10.1111/apt.16596

Chicago

Nakajima, Atsushi, Yuichiro Eguchi, Masato Yoneda, Kento Imajo, Nobuharu Tamaki, Hideki Suganami, Toshiaki Nojima, et al. 2021. “Randomised Clinical Trial: Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), versus Placebo in Patients with Non-Alcoholic Fatty Liver Disease.” Alimentary Pharmacology & Therapeutics 54 (10): 1263–77. doi:10.1111/apt.16596.